XML 65 R52.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Collaborations and Other Arrangements (Details) $ in Thousands, $ in Millions |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Mar. 21, 2021 USD ($) | Feb. 01, 2021 USD ($) item | Mar. 31, 2024 USD ($) | Mar. 31, 2022 USD ($) | Dec. 31, 2020 USD ($) | Oct. 31, 2018 USD ($) item | Jan. 31, 2016 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2024 CAD ($) | Jun. 30, 2023 USD ($) | Mar. 01, 2024 USD ($) | Dec. 31, 2023 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Agreement Fee |  |  |  | $ 35,000 |  |  |  |  |  |  |  |  |  |
Milestone payments, amount |  |  | $ 12,500 |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  | $ 21,955 | $ 23,267 | $ 50,425 |  | $ 57,421 |  |
Royalties due |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 38,400
Cash consideration |  |  |  |  |  |  |  |  |  |  |  |  | $ 170,000 |
Additional consideration |  |  |  |  |  |  |  |  |  |  |  |  | $ 17,800 |
Vaccinex License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payments to be made | $ 3,500 |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate amount payable for achievement of certain regulatory milestones low single digit royalties on global net sales of any approved licensed products | $ 11,500 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Agreement Fee |  |  |  | 35,000 |  |  |  |  |  |  |  |  |  |
Collaboration Agreement | Anti-TIGIT Antibody and IL-2 cytokine |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program |  |  |  | 170,000 |  |  |  |  |  |  |  |  |  |
Adimab Development and Option Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum number of antibodies under for research option | item |  |  |  |  |  | 10 |  |  |  |  |  |  |  |
Minimum Number of Antibodies under Commercialization option | item |  |  |  |  |  | 20 |  |  |  |  |  |  |  |
Minimum antibodies to be commercialized under commercialization option | item |  |  |  |  |  | 1 |  |  |  |  |  |  |  |
Technical milestone payments obligated to pay |  |  |  |  |  | $ 300 |  |  |  |  |  |  |  |
Period for payment of nominal research maintenance fee |  |  |  |  |  | 4 years |  |  |  |  |  |  |  |
Maximum aggregate milestone payments to be made |  |  |  |  |  | $ 13,000 |  |  |  |  |  |  |  |
Maximum antibodies partially exercised under commercialization option | item |  |  |  |  |  | 10 |  |  |  |  |  |  |  |
Percentage of option fee to be paid on partial exercise of commercialization option |  |  |  |  |  | 65.00% |  |  |  |  |  |  |  |
Novartis Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential development milestones |  |  |  |  |  |  | $ 325,000 |  |  |  |  |  |  |
Sales milestones |  |  |  |  |  |  | $ 200,000 |  |  |  |  |  |  |
GSK Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales milestones |  |  |  |  | $ 485,000 |  |  |  |  |  |  |  |  |
Additional clinical milestones eligible to receive |  |  |  |  | 60,000 |  |  |  |  |  |  |  |  |
Regulatory milestones eligible to receive |  |  |  |  | $ 155,000 |  |  |  |  |  |  |  |  |
Term of agreement |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |
GSK Agreement | Surface |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments earned |  |  |  | $ 30,000 |  |  |  |  |  |  |  |  |  |
Junshi Biosciences |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |
Undisclosed preclinical | item |  | 2 |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, royalty on net sales for each exercised option, percentage |  |  |  | 18.00% |  |  |  |  |  |  |  |  |  |
Collaboration agreement, Maximum aggregate one-time payment for achievement of milestones, for each option program |  |  |  | $ 85,000 |  |  |  |  |  |  |  |  |  |
Maximum paid amount for co-development activities (per licensed compound) |  |  |  | $ 25,000 |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  | 0 | $ 3,000 | 4,600 |  |  |  |
Decrease in Research and Development Expenses for Release of Certain Liabilities |  |  |  |  |  |  |  |  |  | 4,800 |  |  |  |
Royalties due |  |  |  |  |  |  |  | 700 |  | 700 |  |  |  |
Junshi Biosciences | Intangible assets, net and accrued and other current liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued milestone payment |  |  | $ 25,000 |  |  |  |  |  |  |  |  |  |  |
Junshi Biosciences | Accrued and other current liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |
Co-development, regulatory and technology transfer costs |  |  |  |  |  |  |  | 12,500 |  | 12,500 |  |  |  |
Junshi Biosciences | Accounts payable |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |
Co-development, regulatory and technology transfer costs |  |  |  |  |  |  |  | 400 |  | 400 |  |  |  |
Junshi Biosciences | Toripalimab (LOQTORZI) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, upfront amount paid |  | $ 150,000 |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, royalty on net sales, percentage |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, Maximum aggregate one-time payments for the achievement of various regulatory and sales milestones |  | $ 380,000 |  |  |  |  |  |  |  |  |  |  |  |
Canada license agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |
Company an upfront payment received |  |  |  |  |  |  |  | $ 6,300 |  | $ 6,300 |  |  |  |
Regulatory and sales milestones eligible to receive |  |  |  |  |  |  |  |  |  |  | $ 51.5 |  |  |
Renewal term |  |  |  |  |  |  |  |  |  | 10 years | 10 years |  |  |

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for milestone payments. + References No definition available. + Details
Name: | chrs_AccruedMilestonePayment
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents co-development, regulatory and technology transfer costs. + References No definition available. + Details
Name: | chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of additional clinical milestones eligible to receive + References No definition available. + Details
Name: | chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum aggregate milestone payments to be made + References No definition available. + Details
Name: | chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds + References No definition available. + Details
Name: | chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of milestone payments earned + References No definition available. + Details
Name: | chrs_CollaborationAgreementMilestonePaymentsEarned
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of undisclosed preclinical immuno-oncology drug candidates under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates
Namespace Prefix: | chrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of option exercise fee per program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementOptionExerciseFeePerProgram
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the percentage of royalty on net sales under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of royalty on net sales for each option program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period for payment of nominal research maintenance fee + References No definition available. + Details
Name: | chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of regulatory milestones eligible to receive + References No definition available. + Details
Name: | chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Renewal term of agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementRenewalTerm
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Technical milestone payments obligated to pay + References No definition available. + Details
Name: | chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Term of agreement + References No definition available. + Details
Name: | chrs_CollaborationAgreementTerm
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents costs associated to a collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationCosts
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of regulatory and sales milestones eligible to receive under the collaborative arrangement. + References No definition available. + Details
Name: | chrs_CollaborativeArrangementRegulatoryAndSalesMilestonesEligibleToReceive
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The upfront payment received by the company under the collaborative arrangement. + References No definition available. + Details
Name: | chrs_CollaborativeArrangementUpfrontPaymentReceived
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of decrease in research and development expenses for release of certain liabilities. + References No definition available. + Details
Name: | chrs_DecreaseInResearchAndDevelopmentExpensesForReleaseOfCertainLiabilities
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of additional consideration received or receivable for product inventory and prepaid manufacturing assets, including discontinued operation. + References No definition available. + Details
Name: | chrs_DisposalGroupIncludingDiscontinuedOperationAdditionalConsiderationForProductInventoryAndPrepaidManufacturingAssets
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the maximum paid amount for co-development activities. + References No definition available. + Details
Name: | chrs_MaximumAmountPaidCoDevelopmentActivities
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum antibodies partially exercised under commercialization option + References No definition available. + Details
Name: | chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption
Namespace Prefix: | chrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum number of antibodies under for research option + References No definition available. + Details
Name: | chrs_MaximumNumberOfAntibodiesUnderForResearchOption
Namespace Prefix: | chrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount per each installment of milestone payments under collaborative arrangements. + References No definition available. + Details
Name: | chrs_MilestonePaymentsAmountPerEachInstallment
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum antibodies to be commercialized under commercialization option + References No definition available. + Details
Name: | chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption
Namespace Prefix: | chrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum Number of Antibodies under Commercialization option + References No definition available. + Details
Name: | chrs_MinimumNumberOfAntibodiesUnderCommercializationOption
Namespace Prefix: | chrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of option fee to be paid on partial exercise of commercialization option + References No definition available. + Details
Name: | chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of potential development milestones entitled. + References No definition available. + Details
Name: | chrs_PotentialDevelopmentMilestonesEntitled
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of regulatory milestones eligible to pay. + References No definition available. + Details
Name: | chrs_RegulatoryMilestonesEligibleToPay
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of sales milestones entitled. + References No definition available. + Details
Name: | chrs_SalesMilestonesEntitled
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details
Name: | us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + References No definition available. + Details
Name: | us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_VaccinexLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_ExclusiveLicenseAndCommercializationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=chrs_AntiTigitAntibodyAndIl2CytokineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_AdimabDevelopmentAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_NovartisAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_GskAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=chrs_SurfaceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=chrs_ToripalimabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_CanadaLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |